title: Plasma plasminogen activator inhibitor-1 levels in the different phenotypes of the polycystic ovary syndrome.
abstract: We aimed to evaluate plasma plasminogen activator inhibitor-1 (PAI-1) antigen levels in women with polycystic ovary syndrome (PCOS) and different levels of adiposity and PCOS phenotypes.  We studied 199 women with PCOS and 50 age-matched healthy women divided in normal weight (n=100 and n=25, respectively) and overweight/obese (n=99 and n=25, respectively).  Normal weight and overweight/obese patients with PCOS were further divided in patients diagnosed according to the 1990 criteria (i.e. with anovulation and hyperandrogenemia; 1990 criteria group) and in patients with the additional phenotypes introduced in 2003 (i.e. with polycystic ovaries and either anovulation or hyperandrogenemia; additional 2003 criteria group).  In normal weight subjects, plasma PAI-1 levels did not differ between women with PCOS (regardless of group) and controls, or between the 1990 criteria and the additional 2003 criteria groups of PCOS.  In overweight/obese subjects, plasma PAI-1 levels were higher in both the 1990 criteria and the additional 2003 criteria groups of PCOS compared with controls (p<0.001 and p=0.004, respectively), but did not differ between the 1990 criteria and the additional 2003 criteria groups of PCOS.  In conclusion, plasma PAI-1 levels are elevated in overweight/obese women with PCOS but not in normal weight women with this syndrome.  Plasma PAI-1 levels do not differ between the phenotypes of PCOS.
authors: Division of Endocrinology and Human Reproduction, Second Department of Obstetrics and Gynecology, Aristotle University of Thessaloniki, Hippokration Hospital, Thessaloniki, Greece.
authors: Ekaterini
authors: E
authors: Koiou
authors: Konstantinos
authors: K
authors: Tziomalos
authors: Konstantinos
authors: K
authors: Dinas
authors: Ilias
authors: I
authors: Katsikis
authors: Eleni A
authors: EA
authors: Kandaraki
authors: Elena
authors: E
authors: Tsourdi
authors: Stylianos
authors: S
authors: Mavridis
authors: Dimitrios
authors: D
authors: Panidis
mesh_terms: D050154:Adiposity; D000328:Adult; D000858:Anovulation / Q000209:etiology; D015415:Biomarkers / Q000097:blood; D015992:Body Mass Index; D015331:Cohort Studies; D005260:Female; D006801:Humans; D017588:Hyperandrogenism; D007333:Insulin Resistance; D009765:Obesity / Q000150:complications; D050177:Overweight / Q000150:complications; D010641:Phenotype; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood*; D011085:Polycystic Ovary Syndrome / Q000097:blood* / Q000150:complications / Q000378:metabolism / Q000503:physiopathology*; D017410:Practice Guidelines as Topic; D055815:Young Adult
chemical_list: D015415:Biomarkers; D017395:Plasminogen Activator Inhibitor 1; C051321:SERPINE1 protein, human